Clinical trial · Interventional
Neoadjuvant Chemotherapy for Resectable Cancer of the Pancreatic Head
NCT00490360CI-TRIAL-00000761completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Neodajuvant chemotherapy with gemcitabine / cisplatin is applied to patients with resectable cancer of pancreatic head.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer of the Pancreatic Head | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Gemcitabine / Cisplatin | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Resectability rate > 70% after restaging
- timeFrame
- 2007
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion criteria: - Age \> 18 years * Histologically or cytologically confirmed resectable ductal adenocarcinoma of the pancreatic head * WHO-performance status 0-2 * Written informed consent * Discussion in an intrdisciplinary conference Exclusion criteria: - Insufficient renal function (calculated creatinin clearance \< 60ml(min) * Insufficient hematologic function (neutrophil count \<1'000/ul, platelets \< 100'000/ul) * Uncorrectable coagulopathy * Severe cholestasis (bilirubin \>100mmol/l) * Distant metastases in liver, lungs or other organs * Peritoneal carcinomatosis * Unresectable tumor (s. 4.2.) * Contraindication for Whipple procedure * Uncontrolled infection * Neurotphil count \> °2 * Estimated life experience \< 6 months * HIV Infection * Severe medical or psychatric comorbidities which interefere with the participation in this trial or the informed consent * Female patients in child-bearing age without adequate contraception
References
Publications (1)
- DERIVEDHeinrich S, Schafer M, Weber A, Hany TF, Bhure U, Pestalozzi BC, Clavien PA. Neoadjuvant chemotherapy generates a significant tumor response in resectable pancreatic cancer without increasing morbidity: results of a prospective phase II trial. Ann Surg. 2008 Dec;248(6):1014-22. doi: 10.1097/SLA.0b013e318190a6da. PMID 19092346